Current Gene Therapy

Ignacio Anegon
Director INSERM UMR 1064-Center for Research in Transplantation and Immunology
CHU de Nantes. 30, boulevard
Nantes
France

Back

Non-Traditional Drug Targets: High Risk, High Reward

Author(s): Tanya Sandrock, Alexander Kamb.

Abstract:

Genomics and proteomics have unveiled a plethora of protein-protein interactions that may control cellular processes involved in disease development. Many of these interactions involve non-traditional candidate targets (i.e., neither enzymes nor cell surface receptors / channels). To date, non-traditional targets have largely been ignored by the pharmaceutical industry or have failed to lead to drugs. This review focuses on the use of transdominant genetically encoded agents and specialized small-molecule drugs to explore this void.

Keywords: transdominant genetics, reverse genetics, protein-protein interaction, non-traditional drug target

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 3
ISSUE: 5
Year: 2003
Page: [395 - 404]
Pages: 10
DOI: 10.2174/1566523034578212
Price: $58